Articles tagged "Induction therapy"

2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
2016 American Transplant Congress
Non-Human Primate Lung Allograft Survival Is Prolonged by IL-6 Inhibition and ATG Treatment Possibly Through Expansion of Peripheral Regulatory T Cells.
A. Aoyama, M. Tonsho, R.-N. Smith, R. Colvin, A. Dehnadi, J. Madsen, A. Cosimi, G. Benichou, T. Kawai, J. Allan.
Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
BACKGROUND: Inflammatory responses have been linked to the development of acute and chronic rejection after lung transplantation in various models. Previous studies have demonstrated that…
2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
H. Wadei,¹ H. Saull,² C. Enderby,² M. Mai,¹ M. Prendergast,¹ T. Gonwa.¹
¹Transplant, Mayo Clinic, Jacksonville, FL; ²Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…
2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
M. Shindorf,¹ D. Fumo,¹ M. Weis,¹ W. Qu,¹ M. Rees,^1,2 J. Ortiz.¹
¹The University of Toledo Medical Center, Toledo, OH; ²The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…
2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
L. Donohue, W. Ally, S. Dunn, J. Kennedy, J. Bergin.
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…
2015 American Transplant Congress
Blood Gene Expression Profiling in a Randomized Controlled Trial of rATG Vs. IL2RA Induction Reveals the Differences in Immune Impact and Mechanisms
K. Chavin,¹ D. Taber,¹ S. Kurian,² T. Gelbart,² N. Pilch,¹ S. Nadig,¹ J. McGillicuddy,¹ T. Srinivas,¹ C. Bratton,¹ P. Baliga,¹ D. Salomon.²
¹MUSC, Charleston, SC; ²Scripps Research Institute, La Jolla, CA.
We performed global gene expression profiling using microarrays on samples from a prospective, RCT designed to study the safety & efficacy of induction with antithymocyte…
2015 American Transplant Congress
Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation
V. Whittaker,¹ D. Halleran,¹ S. Narsipar,¹ J. Melancon.²
¹Surgery, State University New York Upstate Medical University, Syracuse, NY; ²Surgery, George Washington University, Washington, DC.
Purpose: To report one year outcomes from single center experience with a novel induction regimen using anti-thymocyte globulin ( ATG)(rabbit)rATG (3 mg/kg) in divided doses…
2015 American Transplant Congress
Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
D.-A. Moutzouris, L. Koizia, M. Willicombe, R. Corbett, N. Duncan, J. Galliford, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
The use and choice of induction immunosuppression in elderly kidney recipients remains unresolved. Alemtuzumab has been associated with a higher risk of death and graft…
2015 American Transplant Congress
Renal Function Following Basiliximab Induction in Liver Transplant Recipients
J. Hagopian, T. Horwedel, L. Bowman, K. Collins, M. Doyle.
Washington University School of Medicine, St. Louis.
Purpose: Reports of the use of antibody induction to delay the start of calcineurin inhibitor therapy postoperatively in patients with renal insufficiency at the time…
2015 American Transplant Congress
Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab
D. Halleran,¹ J. Melancon,² V. Whittaker.¹
¹Surgery, State University New York Upstate Medical University, Syracuse, NY; ²Surgery, George Washington University, Washington, DC.
Purpose: We report the outcomes from our single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative…